Clincosm LogoSign in Get a demo

PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects

Sponsor
Sanofi (Industry)
Overall Status
Completed
CT.gov ID
NCT03069963
Collaborator
(none)
24
Enrollment
1
Location
2
Arms
1.9
Actual Duration (Months)
12.6
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Primary Objective:

Pharmacodynamics: assessment by pH metry of the change in gastric pH (antacid activity) of Z0063, in comparison to the effect of Gaviscon Double Action Tablets, in healthy adult subjects.

Secondary Objective:

Safety: assessment of the clinical safety of Z0063, and Gaviscon Double Action Tablets, in healthy adult subjects.

Condition or Disease Intervention/Treatment Phase
Phase 1

Detailed Description

The maximal total study duration per subject is 5 weeks and 1 day.

Study Design

Study Type:
Interventional
Actual Enrollment :
24 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
A Randomized, Open Label, 2-Treatment Crossover Study to Compare by pH Metry, the Antacid Activity of the To-be-registered Product (250 mg Sodium Alginate/187.5 mg Calcium Carbonate/106.5 mg Sodium Hydrogen Carbonate, Chewable Tablets) Versus the Registered Gaviscon Double Action Tablets, in Healthy Adult Subject
Actual Study Start Date :
Feb 24, 2017
Actual Primary Completion Date :
Apr 23, 2017
Actual Study Completion Date :
Apr 23, 2017

Arms and Interventions

Arm Intervention/Treatment
Experimental: Sequence 1 (Z0063 to Gaviscon)

The subjects will be given Z0063 single dose and then will crossover to Gaviscon single dose

Drug: Z0063
Pharmaceutical form: chewable tablets Route of administration: oral

Drug: Gaviscon
Pharmaceutical form: chewable tablets Route of administration: oral
Experimental: Sequence 2 (Gaviscon to Z0063)

The subjects will be given Gaviscon single dose and then will crossover to Z0063 single dose

Drug: Z0063
Pharmaceutical form: chewable tablets Route of administration: oral

Drug: Gaviscon
Pharmaceutical form: chewable tablets Route of administration: oral

Outcome Measures

Primary Outcome Measures

  1. Percentage of time at which the intragastric pH is at least equal to or greater than 4 during the 4-hour observation period post-dose [4 hours after the investigational medicinal product (IMP) administration]

Secondary Outcome Measures

  1. Percentage of time at which the intragastric pH is at least equal to or greater than 3 during the 4-hour observation period post-dose [4 hours after the IMP administration]

  2. 4-hour median pH [4 hours after the IMP administration]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 55 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion criteria :

  • Male or female subjects, between 18 and 55 years of age, inclusive.

  • Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 28.0 kg/m2, inclusive.

  • Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination).

  • Normal vital signs, electrocardiogram (ECG) and laboratory parameters.

  • Subject has to accept a gastric probe.

Exclusion criteria:

  • Any history or presence of clinically relevant abnormalities at screening which could interfere with the objectives of the study or the safety of the subject's participation.

  • Blood donation, any volume, within 2 months before inclusion.

  • History or presence of drug or alcohol abuse.

  • Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during the study.

  • If female, pregnancy (defined as positive beta-human chorionic gonadotropin [β-HCG] blood test), breast-feeding.

  • Any medication (including St John's Wort) within 14 days before inclusion, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion.

  • Any subject in the exclusion period of a previous study according to applicable regulations.

  • Any subject who cannot be contacted in case of emergency.

  • Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, anti-hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti-HIV2 Ab).

  • Positive result on urine drug screen.

  • Positive alcohol breath test.

  • Known hypersensitive to alginates, products or formulation excipients, and/or to any component of the standardized meal.

  • Any subject with difficulty in chewing and swallowing.

  • Any subject with strong gag reflex.

  • Any intake of aluminium and magnesium containing antacids or other alginate-containing medicinal products within 14 days before inclusion.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Investigational Site Number 2500001 Gieres France 38610

Sponsors and Collaborators

  • Sanofi

Investigators

  • Study Director: Clinical Sciences & Operations, Sanofi

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Sanofi
ClinicalTrials.gov Identifier:
NCT03069963
Other Study ID Numbers:
  • PDY14362
  • 2015-000763-13
  • U1111-1183-5042
First Posted:
Mar 3, 2017
Last Update Posted:
May 12, 2022
Last Verified:
Jun 1, 2017
Individual Participant Data (IPD) Sharing Statement:
Yes
Plan to Share IPD:
Yes
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Gastroesophageal Reflux
Alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination

Study Results

No Results Posted as of May 12, 2022